Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Tier-Classified Guidelines Database


Genomics & Health Impact Scan Database|Search|Public Health Genomics and Precision Health Knowledge Base (PHGKB)

Last data update: Apr 10, 2024. (Total: 533 Documents since 2012)
   dataset
Filtered By:
Records 1-30 (of 57 Record(s))
Reminder!

The tier level is assigned to the guideline, NOT to the specific search terms. For example, a Tier 1 guideline has at least one recommendation that meets criteria for Tier 1, but also could include tier 2 or 3 recommendations.
DO read the guidelines to find out about specific search terms.
DON’T rely on the overall tier classification of the guideline for the specified search terms.
See More FAQ

Next
Query Trace: Implementation[original query]
Publication Tier
AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review.
Rachel B Issaka et al. Gastroenterology 2023
Tier 2
Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals.
Laura Obici et al. BMJ Open 2023 13(9) e073130
 Tier 2
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.
Gerald F Watts et al. Nat Rev Cardiol 2023
Tier 1
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Chad A Bousman et al. Clinical pharmacology and therapeutics 2023
Tier 2
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Lianne Beunk et al. European journal of human genetics : EJHG 2023
Tier 2
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
Nijenhuis Marga et al. European journal of human genetics : EJHG 2022
Tier 2
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.
Hulshof Emma C et al. European journal of human genetics : EJHG 2022
Tier 2
Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.
van der Pol Karel H et al. European journal of human genetics : EJHG 2022
Tier 2
The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.
Cooper-DeHoff Rhonda M et al. Clinical pharmacology and therapeutics 2022
Tier 2
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.
Lee Craig R et al. Clinical pharmacology and therapeutics 2022
Tier 2
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.
James Paula D et al. Blood advances 2021 Jan 5(1) 280-300
 Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.
Crews Kristine R et al. Clinical pharmacology and therapeutics 2021 Jan
Tier 3
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Philadelphia Prostate Cancer Consensus Conference 2019
 Tier 2
Local Coverage Determination (LCD) for Pharmacogenomics Testing
The Centers for Medicare & Medicaid Services (CMS)
 Tier 1
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg Carin A T C et al. European journal of human genetics : EJHG 2019 28(4) 508-517
 Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
Karnes Jason H et al. Clinical pharmacology and therapeutics 2020 Aug
Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Lima John J et al. Clinical pharmacology and therapeutics 2020 Aug
Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.
Theken Katherine N et al. Clinical pharmacology and therapeutics 2020 Mar
Tier 2
An evidence-based guideline on the application of molecular testing in the diagnosis, prediction of prognosis, and selection of therapy in non-GIST soft tissue sarcomas.
Yao Xiaomei et al. Cancer treatment reviews 2020 Feb 85101987
 Tier 1
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Gori S, et al. Crit Rev Oncol Hematol. 2019 May 25;140:67-72
 Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy.
Brown Jacob T et al. Clinical pharmacology and therapeutics 2019 Feb
Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy.
Desta Zeruesenay et al. Clinical pharmacology and therapeutics 2019 Apr
Tier 2
ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer.
et al. Obstetrics and gynecology 2018 Jan 131(1) e31-e34
 Tier 2
Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.
Yamazaki Kentaro et al. Cancer science 2018 Jun 109(6) 2074-2079
 Tier 2
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Phillips Elizabeth J et al. Clinical pharmacology and therapeutics 2018 Feb
Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz Matthew P et al. Clinical pharmacology and therapeutics 2018 Jan
Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.
Gonsalves Stephen G et al. Clinical pharmacology and therapeutics 2018 Nov
Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
et al. Clinical pharmacology and therapeutics 2018 Feb 103(2) 349
 Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.
Relling Mary V et al. Clinical pharmacology and therapeutics 2018 Nov
Tier 2
Genomic newborn screening: public health policy considerations and recommendations.
Friedman Jan M et al. BMC medical genomics 2017 Feb 10(1) 9
 Tier 3
TOP